Technology ID

Overexpression of Phf19 on T Cells Enhances Therapeutic Effects of T Cell-Based Therapies (such as Chimeric Antigen Receptor [CAR] Therapies)

Lead Inventor
Ji, Yun (NCI)
Gattinoni, Luca (NCI)
Therapeutic Areas
Development Stages
Pre-clinical (in vivo)
Lead IC

T cell-based immunotherapy (such as CAR therapies) is a promising approach for the treatment of several cancers. However, T cells currently employed for various T cell-based immunotherapies are usually senescent and terminally differentiated leading to poor proliferative and survival capacity, limiting their therapeutic effectiveness once transferred into a patient’s blood. 

Researchers in the National Cancer Institute (NCI) Experimental Transplantation and Immunology Branch (ETIB) have epigenetically reprogrammed CD8+ T cell fate by overexpressing Phf19. The inventors found that overexpression of Phf19 in tumor-reactive CD8+ T cells limits T cell terminal differentiation and exhaustion. In addition, it was found that Phf19 overexpressing T cells exhibit enhanced proliferation and cytokine production, resulting in augmented anti-tumor activity in vivo. This technology is available for licensing and/or co-development.

Competitive Advantages:

  • T cells overexpressing Phf19 can increase therapeutic effectiveness of adoptive immunotherapy because it improves T cell proliferation increasing the number of T cells that can be used for T cell-based immunotherapies
  • T cells, overexpressing Phf19 used for immunotherapy in preclinical in vivo studies, are already known to induce a greater decrease in tumor size compared to mice treated with T cell-based immunotherapies using unmodified T cells

Commercial Applications:

  • Treating cancer patients receiving T cell-based immunotherapy 
Licensing Contact: